Biogen is a drug manufacturers - general business based in the US. Biogen shares (BIIB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $154.27 – an increase of 2.55% over the previous week. Biogen employs 7,605 staff and has a trailing 12-month revenue of around $10.1 billion.
Become a Finder member, open a SoFi Active Invest account and make a first deposit of $1,000 or more to receive a $150 gift card. Offer ends November 30, 2025.
T&Cs and limits apply.
Trade stocks, options, ETFs, mutual funds, alternative asset funds
$0 commission on stocks, ETFs and options with no options contract fees
Get up to $1,000 in stock when you open and fund a new account within 30 days
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Must be a SoFi Plus member at the time a recurring deposit is received into your SoFi Active or Automated investing account to qualify. Bonus calculated on net monthly recurring deposits made via ACH and paid out as Rewards Points. See Rewards Terms of Service. SoFi reserves the right to change or terminate this promotion at any time without notice. See terms and limitations. https://www.sofi.com/sofiplus/invest/#disclaimers
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – BIIB.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Biogen stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
5 of 5 results
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Biogen stock price (NASDAQ: BIIB)
Use our graph to track the performance of BIIB stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Biogen price performance over time
Historical closes compared with the close of $154.27 from 2025-10-31
1 week (2025-10-28)
3.45%
1 month (2025-10-03)
-3.51%
3 months (2025-08-04)
16.69%
6 months (2025-05-02)
24.88%
1 year (2024-11-04)
-11.09%
2 years (2023-11-03)
-38.17%
3 years (2022-11-04)
281.82
5 years (2020-11-04)
355.63
Is Biogen stock undervalued or overvalued?
Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biogen's P/E ratio
Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Biogen shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Biogen's PEG ratio
Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Biogen's EBITDA
Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.4 billion.
The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.
Biogen financials
Revenue TTM
$10.1 billion
Operating margin TTM
30.72%
Gross profit TTM
$7.7 billion
Return on assets TTM
5.75%
Return on equity TTM
9.31%
Profit margin
15.98%
Book value
$124.11
Market Capitalization
$22.6 billion
TTM: trailing 12 months
Biogen's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Biogen.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Biogen's total ESG risk score
Total ESG risk: 22.95
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Biogen's overall score of 22.95 (as at 12/31/2018) is pretty good – landing it in it in the 34th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Biogen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Biogen's environmental score
Environmental score: 1.02/100
Biogen's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Biogen's social score
Social score: 13.48/100
Biogen's social score of 13.48 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Biogen's governance score
Governance score: 7.45/100
Biogen's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Biogen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Biogen's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Biogen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Biogen has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Biogen Inc was last rated for ESG on: 2019-01-01.
Total ESG score
22.95
Total ESG percentile
33.82
Environmental score
1.02
Environmental score percentile
2
Social score
13.48
Social score percentile
2
Governance score
7.45
Governance score percentile
2
Level of controversy
2
Biogen share dividends
We're not expecting Biogen to pay a dividend over the next 12 months.
Have Biogen's shares ever split?
Biogen's shares were
split on a 3:1 basis on 17 January 2001
. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.
Biogen share price volatility
Over the last 12 months, Biogen's shares have ranged in value from as little as $110.04 up to $179.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is 0.125. This would suggest that Biogen's shares are less volatile than average (for this exchange).
Biogen overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.
Frequently asked questions
null What percentage of Biogen is owned by insiders or institutions? Currently 0.149% of Biogen shares are held by insiders and 93.291% by institutions.How many people work for Biogen? Latest data suggests 7,605 work at Biogen.When does the fiscal year end for Biogen? Biogen's fiscal year ends in December.Where is Biogen based? Biogen's address is: 225 Binney Street, Cambridge, MA, United States, 02142What is Biogen's ISIN number? Biogen's international securities identification number is: US09062X1037What is Biogen's CUSIP number? Biogen's Committee on Uniform Securities Identification Procedures number is: 449370105
Discover the five main types of dividends, how taxes work and how your portfolio can benefit from these regular profit payouts to shareholders.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
